Based on a new study of the safety and abuse potential of psilocybin, the hallucinogenic drug in magic mushrooms, Johns Hopkins University School of Medicine researchers recommend that "psilocybin should be re-categorized from a schedule I drug—one with no known medical potential—to a schedule IV drug such as prescription sleep aids, but with tighter control."
From Johns Hopkins
"We want to initiate the conversation now as to how to classify psilocybin to facilitate its path to the clinic and minimize logistical hurdles in the future," says Matthew W. Johnson, associate professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine. "We expect these final clearance trials to take place in the next five years or so."
Following the Controlled Substances Act of 1970, any drug with the potential for abuse is categorized based on criteria that take into account whether the drug has accepted medical use, and its safety and the potential for abuse. Schedule IV drugs are those that have a low potential for abuse or dependence.
Although preliminary research studies suggest that psilocybin may be effective for smoking cessation and for disorders such as cancer-specific depression and anxiety, it must clear phase III clinical trials before the Food and Drug Administration can be petitioned to reclassify it.
Highlights from their scientific paper published in the journal Neuropharmacology:
• Psilocybin mushrooms have been used for millennia for spiritual and medical purposes.
• Animal and human studies indicate low abuse and no physical dependence potential.
• Major national surveys indicate low rates of abuse, treatment-seeking and harm.
• Psilocybin may provide therapeutic benefits supporting its development as a new drug.
• Analysis supports the scheduling of psilocybin no more restrictively than Schedule IV.
NASA released this incredible image of the sky that depicts 22 months of X-ray data captured from the International Space Station using the Neutron star Interior Composition Explorer (NICER). From NASA: “Even with minimal processing, this image reveals the Cygnus Loop, a supernova remnant about 90 light-years across and thought to be 5,000 to 8,000 […]
In the realm of rocket geeks and space nerds, filmmakers MaryLiz Bender and Ryan Chylinski have dream jobs. The pair have the equivalent of “backstage passes” to SpaceX, NASA and ULA rocket launches where they capture and share breathtaking videos that convey the power, risk, and thrill of space exploration. The work of their studio, […]
The 1990s nanotechnology dream of tiny robots swimming through our blood stream to treat disease is moving (verrrry) slowly but surely toward reality. In a new milestone, researchers used an external magnetic field to steer microbots through a live mouse’s body carrying therapeutic stem cells. From IEEE Spectrum: ..Delivering stem cells typically requires an injection […]
Even if you feel like AirPods are worth the price tag, you’ve got to admit there’s a certain anxiety that comes with using them. What if I lose them? What if they get wet in the rain? Or drenched in sweat? Or fall into the drink you dropped them into? Shiny tech is great, but […]
With the quick-fix appeal of video games and their own cell phones, it can be tough to keep kids focused on supposedly “educational” toys. And while it may seem counter-intuitive to fight tech with more tech, we’re all in when it comes to the Toybox 3D Printer. We’re not sure if anyone had envisioned a […]
Whether you’re an artist, designer or just organizing a photo album, photo editing software is a must. And software designers know it: Platforms like Photoshop and Lightroom have a ton of helpful features, but you’ll pay for them in spades. Luckily, there’s some competition in the photo editing arena. Right now, Skylum’s Luminar software is […]